Mainz, Rhineland-Palatinate, Germany – Prof. Dr. Ugur Sahin, Professor for Translational Oncology and Immunology at University Medical Center Mainz, shared the good news for the vaccine BNT162b2, effectively prevent COVID-19.

A great day for mankind! The Data Monitoring Committee of our global Phase 3 study conducted its first interim analysis which provides evidence that our vaccine #BNT162b2 may effectively prevent #COVID-19.

The case split between vaccinated individuals and those who received placebo indicates a vaccine efficacy rate above 90% at 7 days after the 2nd dose. This is a victory for science, technology, innovation and our global collaborative effort. When we embarked on this journey 10 months ago, this is what we aspired to achieve. Especially today, while we are all in the midst of a 2nd wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will collect further data as the trial continues to enroll for a final analysis planned when 164 COVID-19 cases have accrued. We continue to work with regulatory authorities around the world to plan the next steps.

On behalf of the entire BioNTech SE family, I want to express my gratitude to everyone contributing to this mission, which requires both courage and humbleness. We continue to count on your dedication as the beginning of the end of the pandemic appears to rise on the horizon. Please stay safe and healthy.